In 2022, Cuu Long Pharmaceutical Joint Stock Company (Cuu Long Pharmaceutical, stock code DCL) achieved VND 1,016 billion in revenue, equivalent to 144% over the same period last year. This is the highest revenue of the Company during 46 years of operation.

Accordingly, information from Cuu Long Pharmaceutical said that in 2022, the Company was estimated to achieve revenue of VND 1,016 billion and profit before tax of VND 140.5 billion. With this result, Cuu Long Pharmaceutical exceeded 20% and 5% of the plan in terms of revenue and profit in 2022 respectively, of which 44% of revenue and 27% of profit were increased over the same period last year.

Mr. Luong Trong Hai, General Director of Cuu Long Pharmaceutical, said that the business results in 2022 are very encouraging achievements for the entire Leadership and employees of the Company.

“This is not only an important milestone in the progress of Cuu Long Pharmaceuticalin terms of operating revenue scale, but the achievement of the 1000 billion VND revenue milestone in the context of complicated fluctuations in the world and domestic economic situation also shows the great efforts of the whole Company. The great thing is that those efforts have paid off,” Hai said.

The three core business segments that contribute significantly to Cuu LongPharmaceutical’sbusiness results structure are pharmaceuticals, capsules, and medical equipment supplies. Among these, Cuu Long Pharmaceutical is currently the only enterprise in Vietnam to produce capsules. The Company’s factories are equipped with advanced Canada-imported technology, and they are in a state of full capacity.

Last year, the Company invested in the expansion of Phase 5 with a capital of VND 232.5 billion and a capacity of 2.8 billion capsules/year to meet the needs of customers. It is expected that by the end of the second quarter of 2023, the project will come into operation.

Cuu Long Pharmaceutical is currently the only enterprise in Vietnam to produce capsules.

For the medical equipment segment, in addition to the existing factories, the Company has been investing in a medical supplies and equipment factory on an area of 10,846.6 m2 in Vinh Long with an investment capital of approximately USD15 million. The project is divided into two phases, including Phase 1: capacity of 35 million products/month; and Phase 2: Capacity of 20 million products/month. This factory is planned to be completed and put into operation in the third quarter of 2023.

Thus, right in 2023, with the commissioning of two new factories related to capsules and medical equipment supplies, Cuu Long Pharmaceutical is expected to create a breakthrough at the operating scale to create a premise for strong growth in revenue from the end of 2023 onwards.

In addition to the two new factories that are preparing to be put into operation, Cuu Long Pharmaceutical is also continuing to invest in a pharmaceutical factory under EU-GMP standards in Long An. The project will include a R&D and pharmaceutical product production center with a production capacity of 1.6 billion products per year.

Current Cuu Long Pharmaceutical Factory

According to Cuu Long Pharmaceutical, the synchronous investment in factories from the R&D stage aims to research, develop, and improve products to meet market needs and catch up with other companies in timely research and development of high-quality products and meet new needs and trends in the market. This will be one of the important platforms to support the operation of the entire Cuu Long Pharmaceutical in general and the pharmaceutical factory in Long An in particular and create a premise to improve the competitiveness and position of the Company’s products in the market.

With its business strategies and projects being promoted, in 2023 and beyond, Cuu Long Pharmaceutical promises to make great strides to bring consumers products of even superior quality to contribute to protecting and improving the quality of life in the community.

Established in 1976, with 46 years of operation in the field of pharmacy, Cuu Long Pharmaceutical has become a familiar and prestigious name to consumers and pharmacies and is a reputable and long-term pharmaceutical supplier for many major hospitals in Vietnam. Cuu Long Pharmaceutical’s product distribution network is spread across 63 provinces and cities.

Thanks to the strong investment from F.I.T Group, Cuu Long Pharmaceutical aims to become the leading pharmaceutical enterprise in Vietnam in the production of pharmaceuticals and medical devices through constantly researching and developing new product lines, owning advanced machinery systems, and building a professional personnel system.

Website: www.dcl.com.vn/